Brief: AstraZeneca Says Tagrisso® (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial
BRIEF-AstraZeneca Says Tagrisso® (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial Sept 13 (Reuters) - AstraZeneca PLC AZN.L:
TAGRISSO® (OSIMERTINIB) DEMONSTRATED UNPRECEDENTED EIGHT-YEAR LANDMARK SURVIVAL IN EARLY-STAGE EGFR-MUTATED LUNG CANCER IN ADAURA PHASE III TRIAL
ASTRAZENECA - REPORTS LONGEST SURVIVAL DATA IN GLOBAL PHASE III TRIAL FOR EARLY-STAGE EGFR-MUTATED LUNG CANCER
ASTRAZENECA - TAGRISSO REDUCES RISK OF DEATH BY 47% IN STAGES II-IIIA AT EIGHT YEARS
ASTRAZENECA - TAGRISSO REDUCES RISK OF DEATH BY 48% IN STAGES IB-IIIA AT EIGHT YEARS
ASTRAZENECA - 74% OF TAGRISSO-TREATED PATIENTS ALIVE AT EIGHT YEARS IN STAGES II-IIIA
ASTRAZENECA - 79% OF TAGRISSO-TREATED PATIENTS ALIVE AT EIGHT YEARS IN STAGES IB-IIIA
ASTRAZENECA - ADAURA FINAL SAFETY DATA SHOW TAGRISSO PROFILE CONSISTENT WITH NO NEW SAFETY CONCERNS
Source text: ID:nBw2RsjVra
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines